![Jakob Dynnes Hansen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jakob Dynnes Hansen
Director Financiero/CFO en ASARINA PHARMA AB .
Cargos activos de Jakob Dynnes Hansen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ASARINA PHARMA AB | Director Financiero/CFO | 01/04/2017 | - |
NANEXA AB | Director/Miembro de la Junta | 01/01/2023 | - |
Independent Dir/Board Member | 01/01/2023 | - | |
Zerion Pharma A/S | Director Financiero/CFO | - | - |
Historial de carrera de Jakob Dynnes Hansen
Antiguos cargos conocidos de Jakob Dynnes Hansen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
GALECTO, INC. | Secretario Corporativo | - | 01/04/2020 |
EVOLVA HOLDING SA | Director Financiero/CFO | 15/12/2009 | 31/12/2016 |
Allylix, Inc.
![]() Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Director/Miembro de la Junta | - | - |
Director Financiero/CFO | - | - | |
Unibank (Denmark) | Director Financiero/CFO | 28/12/2010 | - |
Director de Investigación - Fxd Inc | - | 28/12/2010 | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Director Financiero/CFO | 01/09/2007 | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
░░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
Formación de Jakob Dynnes Hansen.
INSEAD | Masters Business Admin |
University of Copenhagen | Graduate Degree |
Estadísticas
Internacional
Dinamarca | 7 |
Estados Unidos | 3 |
Suiza | 3 |
Operativa
Director of Finance/CFO | 8 |
Director/Board Member | 2 |
Graduate Degree | 1 |
Sectorial
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 6 |
---|---|
NOVO NORDISK A/S | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
EVOLVA HOLDING SA | Consumer Non-Durables |
ASARINA PHARMA AB | Health Technology |
NANEXA AB | Health Technology |
GALECTO, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Allylix, Inc.
![]() Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Health Technology |
Unibank (Denmark) | Finance |
Nuevolution AB
![]() Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Zerion Pharma A/S |
- Bolsa de valores
- Insiders
- Jakob Dynnes Hansen
- Experiencia